cyrilzakka/clinical-trials huggingface dataset:
The Role of Skin Care Regimen in Skin Health

This research is being done to evaluate the role of a regular skin care regimen comprising of a mild soap and moisturizer in improving dry skin and overall skin health. In this study, the investigators hope to learn the importance of regular skin care regimen in improving dry skin and overall skin health.

Dry skin is a common phenomenon and can dramatically decrease a person's quality of life as well as contribute to a wide variety of skin diseases. Skin care products hydrate the skin and breaks the dry skin cycle. While there is extensive evidence of benefits of using mild cleansers and moisturizers, much of the previous studies are limited to the effects of single cleanser or moisturizer.

In this study, the investigators are going to enroll up to 100 people over the age of 18 with dry, itchy skin and they will be split into 2 groups. Participants will be randomly assigned to skin care regimen group (approximately 75% of total enrolled) and control group (approximately 25% of total enrolled). All evaluation include clinical assessments, subject questionnaires and photography will be conducted similarly in both groups.

Analysis will include paired and unpaired t-tests with two-tailed p-values. Values obtained at baseline, in middle of the study and after completing the study will be compared. The difference of measure values will be compared between application group and control group.

The moisturizing lotion and wash are generally very well tolerated.Rarely, they can induce a burning sensation, dryness, skin irritation, erythema, stinging, sensitization, and dermatitis. Risk events, problems, and deviations will be reported by the PI directly to the Institutional Review Boards.

The investigators hope to learn the importance of regular skin care regimen in improving dry skin and overall skin health.

Eligibility Criteria:
Inclusion Criteria:

* Participants must be over the age of 18 years old with dry, itchy skin;
* Participant must be willing to comply with the requirements of the protocol;
* Participant must have the ability to understand and communicate with the investigator;
* Participant must provide informed consent.

Exclusion Criteria:

* Subjects who are unable to provide informed consent;
* Subjects who are unable to refrain from swimming or hot tub use throughout the study duration
* Subject with significant medical history or current skin diseases that the investigator feels is not safe for study participation;
* Subjects who have been treated with systemic retinoids or steroids within the past month prior to entry to the study;
* Subjects who have been treated with topical steroids, retinoids or other topical drugs within 2 weeks prior to entry to the study;
* Recently treated or current skin diseases that would affect clinical evaluation;
* Subjects who self-report that they are pregnant or nursing;
* Patients with history of investigational drug use in the 30 days prior to entry into the study.
Use of Extracellular Vesicles (EV) for Knee Osteoarthrosis

Extracellular vesicles (EV) will be injected in patients diagnosed with Knee osteoarthrosis

50 patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. These patients will be injected with Extracellular vesicles (EV). Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.

Eligibility Criteria:
Inclusion Criteria:

* Severe KOA stage III or IV by Laurance \& Kellgren staging as judged by Posterioranterior (PA) Xray of the knee joint.
* Willing to participate by signing the informed consent

Exclusion Criteria:

* Sublaxation beyond 20 degrees of the bones of the knee joint
* Oral anticoagulants or heparin therapy
* Heart failure or arrhythmia
* Body Mass Index \> 35
* Uncontrolled Diabetes Mellitus.
* Evidence of Infectious Diseases.
* Active infection
* Malignancy
* Pregnancy
* Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than 3000.
* Unreliable patients
* Non-resident in Jordan
Hyaluronic Acid Delivery: CO2 Laser Versus Thulium Laser Treatment

* Weakly crossed-linked hyaluronic acid (HA) can be delivered through multiple injections into the dermal and subnormal layer to improve skin quality. However, this treatment comes with multiple bumps for several days.
* Alternatively, HA can be delivered after CO2 laser or thulium laser pretreatment. As microscopic analysis after this treatment is limited, the object of the present study is to investigate the morphological cellular changes after CO2 laser and thulium laser delivered HA into human skin.


Eligibility Criteria:
Inclusion Criteria:

- healthy male and female patients

Exclusion Criteria:

* pregnancy, breast feeding
* open wounds at the area to be treated
Evaluation of Clinical Significance and Feasibility of CT Guided Biopsy of Double Site Lesions：A Preliminary Lung Centered Study

This study aims to explore the clinical significance and feasibility of double site biopsy by analyzing the pathological characteristics and the incidence of main complications of CT guided puncture biopsy of lung and other parts coexisting lesions.

CT guided biopsy is minimally invasive, accurate and low cost. It is often used as an important diagnostic method when the clinical suspect of malignant disease or the treatment effect of the disease is not good. In patients with suspected malignant lung disease, metastasis of other parts of lung, pulmonary door, mediastinum, bone, and distant soft tissue may be combined at the same time. It is the key link of clinical work to evaluate the nature of these coexisting lesions accurately and choose appropriate treatment methods. At present, there is little clinical study on lung centered double site biopsy. This study aims to explore the clinical significance and feasibility of double site biopsy by analyzing the pathological characteristics and the incidence of main complications of CT guided puncture biopsy of lung and other parts coexisting lesions.

Eligibility Criteria:
Inclusion Criteria:

* patients with suspected malignancy
* underwent dual site CT guided biopsy in the Third Hospital of Peking University

Exclusion Criteria:

-
Profile of Marketing Professional Audiologist Who Works in the Area of Audiology Clinic

the audiology has achieved a great advance, where currently speech pathologists act in private clinics and in public services, in addition to schools, colleges and universities. To observe the development of the area of Audiology in Brazil, we note that there is a growing number of new audiology procedures. In 1980 the practice of audiology was limited in hospitals, offices and private clinics, and in 1988 due to a new constitution that devoted attention to protection of health of workers, opened-if more than one field of work, the audiology occupational, because of the hearing losses induced by noise

The area of audiology referred-if the science of hearing, auditory processing and corporal balance. The speech pathologist, Especialista em Audiologia, identifies, assesses and rehabilitation, empowering people with disabilities peripheral or central auditory, influencing the emergence of human communication disorders, as well as the balance disorders

Eligibility Criteria:
Inclusion Criteria:

* the professionals working with clinical audiology

Exclusion Criteria:

* the professionals who do not act in the city of Fortaleza or refuse to sign the Term of Free and Informed Consent
Life Story Book With Mentally Alert Residents of Nursing Homes

The objective of this study is to study the effects of the Life Story Book intervention on depressive symptoms and meaning in life for mentally alert residents of nursing homes.

Two nursing homes were recruited to participate. One nursing home will receive the Life Story Book intervention while the other half receives Usual Care intervention. The interventions were then switched, and the participants who received Usual Care intervention received the Life Story Book intervention while the home that received Life Story Book intervention received Usual Care intervention. The study consisted of two treatment periods of 3 weeks separated by a washout period of 1 week.

Life Story Book provides a person with the opportunity to chronologically share their life experiences and memories. This three-1 hour reminiscence intervention is designed to provide a person with the opportunity to review their past and capture their life story into something tangible. The Life Story Book includes a combination of written information, photographs of significant people, places or events, and personal narratives from the stages of life that the person would like to include.

Eligibility Criteria:
Inclusion Criteria:

* Ability to speak English
* A resident of the nursing home
* A score of 4 or higher on the Six-Item Screener

Exclusion Criteria:

* A score of 4 or higher on the Six-item Screener
Spanish Cohort of Patients with HIV Infection Older Than 50 Years for the Study of Fragility and Physical Function

It's a prospective observational study to assess frailty and physical function

We stimate to recruit 1120 patients older tan 50 years to assess frailty and define a simplified fragility index

Eligibility Criteria:
Inclusion Criteria:

1. Patients with confirmed HIV + infection.
2. Patients aged ≥ 50 years at the time of starting the study, followed in the Infectious-HIV consultations of the centers participants.

   This limit has been chosen because it is accepted by the scientific community for define the elderly patient in patients with HIV infection.
3. Have signed the informed consent and be willing to comply with the study visits.

Exclusion Criteria:

1. Have an established disability that does not allow you to walk.
2. Patients who can not comply with the visits and study procedures or who are not usually followed at the center.
Video Intervention Fertility Awareness Training

This study was planned to evaluate the effects of video-based ovarian reserve awareness training applied to midwifery students on ovarian reserve, fertility awareness and anxiety of midwifery students. The research population will consist of second-year students studying in the Department of Midwifery, Hamidiye Faculty of Health Sciences (HSBF), Health Sciences University (SBU) in the fall semester of 2024-2025 academic year (N: 80). In this study planned as a semi-experimental pre-test and post-test design with a control group, in order to determine the sample size; the data were normally distributed, the standard deviation of the main mass was estimated as 1 and the effect size (effect size, difference) was estimated as 0.8. For the analysis to be conducted, it was calculated that the highest power value of the study would be 0.942182 if two independent n₁=40, n₂=40 samples were taken at a significance level of 5%. The G-power analysis result is given below.

Students who volunteer to participate in the study will be assigned to the intervention and control groups with the computer-aided simple random sampling method. Computer-aided randomization will be used in the study, and the number of cases will be entered through the program with the URL address https://www.randomizer.org and random assignment will be made to the intervention and control groups. The study will be conducted single-blind. Midwifery students in the intervention group of the study will be given video-based ovarian reserve and fertility awareness training. A pre-training information meeting will be held with midwifery students who volunteered to participate in the study and were assigned to the intervention group. The midwifery students will be administered the "Ovarian Reserve Information Form", "Fertility Awareness Scale" and "State Anxiety Scale" before and after the training.


Eligibility Criteria:
Inclusion Criteria:

* To be a volunteer to participate in the research.
* To be an active student in the 2nd year of the Midwifery Department of Hamidiye Health Sciences Faculty, University of Health Sciences.

Exclusion Criteria:

* Being a passive student in the 2nd year of the Midwifery Department of Hamidiye Health Sciences Faculty, University of Health Sciences.
Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System

The objective of this study is to assess the safety and effectiveness of the Endologix Nellix® System for the endovascular repair of infrarenal abdominal aortic aneurysms (AAA).

This study will evaluate the safety and effectiveness of the Nellix System among a wide range of physicians and in consecutively enrolled subjects to assess outcomes generalizability. Following appropriate government and ethics committee/IRB approval the Nellix® EndoVascular Sealing System will be implanted into eligible patients who are adequately informed and have consented to join the study. Enrolled patients will undergo a high resolution, contrast-enhanced computed tomography angiography (CT) scan of the relevant aortic and aortoiliac vasculature within three months of the scheduled procedure and at specified follow-up intervals post-implantation. Follow-up visits will occur at 30 days, 6 months, and annually to 5 years to assess aneurysm morphology, the status of the implanted devices, and relevant laboratory test results.

Eligibility Criteria:
Inclusion Criteria:

* Male or female at least 18 years old;
* Informed consent understood and signed;
* Patient agrees to all follow-up visits;
* Have AAA with sac diameter ≥5.0cm, or ≥4.5 cm which has increased by \>1.0cm in the past year.
* Anatomic eligibility for the Nellix System per the instructions for use:
* Adequate iliac/femoral access compatible with the required delivery systems (diameter ≥6 mm);
* Aneurysm blood lumen diameter ≤60mm;
* Most caudal renal artery to aortoiliac bifurcation length ≥100mm;
* Proximal non-aneurysmal aortic neck: length ≥10mm; lumen diameter 18 to 32mm; angle ≤60° to the aneurysm sac;
* Common iliac artery lumen diameter between 9 and 35mm with blood lumen diameter ≤35mm;
* Ability to preserve at least one hypogastric artery.

Exclusion Criteria:

* Life expectancy \<2 years;
* Psychiatric or other condition that may interfere with the study;
* Participating in enrollment of another clinical study
* Known allergy to device any device component;
* Coagulopathy or uncontrolled bleeding disorder;
* Ruptured, leaking or mycotic aneurysm;
* Serum creatinine level \>2.0mg/dL;
* CVA or MI within three months of enrollment/treatment;
* Aneurysmal disease of the descending thoracic aorta;
* Clinically significant infrarenal mural thrombus (\>5mm thickness over \>50% circumference);
* Connective tissue diseases (e.g., Marfan Syndrome)
* Unsuitable vascular anatomy;
* Pregnant (females of childbearing potential only).
A Study of Lubiprostone to Treat Constipation

The main aim of this study is to check the side effects from lubiprostone in adults with constipation. Participants will be treated with lubiprostone according to their clinic's standard practice.

This is a prospective, observational post-marketing surveillance study of lubiprostone in participants with constipation. The study will assess the safety and effectiveness of lubiprostone for its approved indication with real-world setting in South Korea.

The study will enroll approximately 3000 participants. The data will be collected prospectively at the study sites will be recorded into electronic case report forms (e-CRFs). All the participants will be assigned to a single observational cohort:

• All Participants

The study will be conducted in South Korea. The overall duration of the study will be approximately 6 years. Data collection will be based on routinely scheduled visits during a 12-month follow up period for each participant up to a final follow-up when the participant discontinues treatment or at the end of follow-up period for any participants still taking lubiprostone.

NOTE: This product was divested from Takeda to Jeil in 2022.

Eligibility Criteria:
Inclusion Criteria:

1. South Korean adult.
2. With constipation caused by:

   * Chronic Idiopathic Constipation (CIC), or
   * Opioid-Induced Constipation (OIC) from treatment for chronic, non-cancer pain, including participants with chronic pain related to prior cancer or its treatment who do not require frequent (example weekly) opioid dosage escalation.
3. Is newly prescribed (first incident) and initiates lubiprostone for the treatment of constipation.

Exclusion Criteria:

1. Treated with lubiprostone outside of the locally approved label in South Korea.
2. Participating in any other clinical study investigating one (or more) of the approved indications of lubiprostone.
Randomized Study of Hormonal Regulation of Infantile Hemangioma

OBJECTIVES: I. Evaluate the clinical efficacy of leuprolide, a gonadotropin-releasing hormone agonist (GnRHa), in treating infants with vision-endangering or large, disfiguring hemangiomas.

II. Assess the impact of GnRHa on growth and development during infancy. III. Assess the safety of GnHRa in these patients.

PROTOCOL OUTLINE: This is a randomized, placebo-controlled study. Patients are stratified according to gender and by position of the lesion (periorbital vs nonperiorbital).

All patients receive oral prednisone daily for 3 weeks. Patients are then randomized to receive either placebo or leuprolide IM every 3 weeks, while continuing oral prednisone. Tumors are assessed at 1, 3, and 6 weeks. If the tumor is not responding, the leuprolide will be administered every 2 weeks. Tumors are reassessed at 3 and 6 months, at which point the treatment is stopped. Responding patients are observed every 3 weeks for 3 months. If the tumor begins to grow again, leuprolide may be administered for another 3 months. Patients whose tumors grow rapidly during treatment may crossover to the alternate therapy, repeat the leuprolide or prednisone therapy, or undergo surgical excision.

Eligibility Criteria:
* Presence of hemangioma meeting at least one of the following criteria: Vision-threatening because of induced astigmatism or occlusion of the visual axis or proptosis Severe anatomic distortion compromising function of an organ or creating an unacceptable cosmetic outcome Other complications, e.g., Kasabach-Merritt consumptive coagulopathy, high-output heart failure, etc.
* No lesions that are clearly regressing before therapy
* No vascular malformations other than juvenile hemangiomas
Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Postoperative of the Thyroidectomy.

Observational study with non-inferiority, prospective, randomized (1: 1) and open-label medical device. The study has 2 treatment groups (HEMOPATCH® versus standard hemostasis).

The main objective is to determine if there is a reduction in the volume of exudate in the surgical bed with the application of the collagen and polyethylene glycol hemostatic agent.

The present study includes patients undergoing total thyroidectomy for multinodular goiter in the Endocrine Surgery Unit of the Virgen del Rocío University Hospital.

The estimated sample calculation of patients enrolled in the study is 108 (2 groups, 1:1 ratio).

The patients don´t know what type of hemostatic the patients are going to receive (single blind).

The duration of patient follow-up will be 30 +/- 10 days after surgery.

Eligibility Criteria:
Inclusion Criteria:

* Patients of legal age.
* Indication of total thyroidectomy due to multinodular goiter.
* Accept to enter the study and sign the informed consent.
* Patient willing and able to complete clinical trial procedures, as described described in the protocol.

Exclusion Criteria:

* Patients under 18 years of age.
* Patients with surgical indication for hemithyroidectomy or subtotal thyroidectomy (eg unilateral nodular goiters).
* Multinodular goiter with high suspicion or preoperative diagnosis of cancer (Bethesda V and VI and / or infiltration of neighboring structures on imaging tests).
* Known allergy or hypersensitivity to a component of the Hemopatch® investigational treatments, riboflavin, or bovine proteins.
* Concurrent or prior therapy with systemic pharmacological agents that promote blood clotting, including, but not limited to, tranexamic acid, activated factor VII, fibrinogen, and aprotinin.
* Pregnancy or breastfeeding.
* Refuse to enter the study and sign the informed consent.
* Not agreeing to carry out all the planned follow-up.
* Concurrent participation in another clinical trial with a medical device or drug or with interfering endpoints Inability to understand the nature and scope of the trial and the required procedures.

Criteria to be verified during surgery (Intraoperative exclusion criteria):

* Persistent major bleeding after primary hemostasis.
* Infection of the surgical area.
Clinical Comparison of Composite Materials

Universal adhesive solutions have just entered the market, allowing dentists to choose an adhesive strategy based on the needs of patients and clinical situations. Theses adhesives contain a primer/adhesive resin mix in a single bottle for multi-mode etch-and-rinse or self-etch applications. The aim of this study was to evaluate the clinical performance of composite resins with diffent adesive agents on Class II cavities.

This study was a double-blind (evaluator and patient) randomized controlled clinical study with six study groups with an equal allocation. Two composite materials with two universal and one two-step self-etch adhesives were compared in Class II restorations.

The treated patients were called back for controls after one week, six months, and eighteen months. Restorations were evaluated clinically according to modified FDI criteria. In terms of esthetic property, marginal discoloration; in terms of function properties, fracture and retention, and marginal adaptation; in terms of the biological characteristics, post-operative sensitivity, and secondary caries criteria were examined.

Clinical evaluation was performed by two qualified clinicians. Bite-wing radiographs were taken from the patients who were called for controls at 6-moth and 18-month to evaluate the formation of secondary caries.

Differences between adhesives at each time period were evaluated using Fisher's Exact test. The effect of time on restorations was evaluated using the Friedman test (p \< 0.05).

Eligibility Criteria:
Inclusion Criteria:

* Individuals without systemic disease
* Individuals with good oral hygiene
* Must be a minimum of one carious defect
* Must be at least 18 years old
* Must have vital teeth in antagonist and proximal contact.

Exclusion Criteria:

* Pregnant or breastfeeding women
* Receiving orthodontic treatment
* Bruxism habit
* Direct or indirect pulp coverage
* Allergy to resin-based products